Loading stock data…
Charles River Laboratories International (CRL)
$226.58-2.71 (-1.18%)
Market ClosedLast close Jul 24
Charles River Laboratories International, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Charles River Laboratories International, Inc. in the Healthcare sector is trading at $226.58 with a market capitalization of $9.0B. Wall Street consensus targets $230.93 (15 analysts), implying a +1.9% move over the next 12 months. The stock is currently near its 52-week high of $238.85, remaining 22.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $995.83M↑ | $994.23M↓ | $1.00B↓ | $1.03B↑ | $984.17M |
| Gross Profit | $294.66M↓ | $309.68M↓ | $338.79M↓ | $357.07M↑ | $317.73M |
| Operating Income | $119.90M↑ | $92.53M↓ | $133.80M↑ | $100.13M↑ | $74.67M |
| Net Income | -$14.84M↑ | -$276.56M↓ | $54.42M↑ | $52.33M↑ | $25.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.28%
Volume
Today's trading volume
382,337
Recent News
HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised
HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
3 Healthcare Stocks We Approach with Caution
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 10.2% over the past six months while the S&P 500 was up 7.7%.
Charles River Laboratories Earnings Preview: What to Expect
Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.